Assignment: Schizophrenia Critical Review
PSYC 6022 - Psychopharmacology
University of Cincinnati
According to the American Psychiatric Association, Schizophrenia is
a “chronic brain disorder that affects less than 1% of the U.S.
population” (American Psychiatric Association, 2017, para. 1). As of
now, the cause(s) of schizophrenia are not known however it is
considered an ‘polygenetic disorder’ which means that schizophrenia
has many different causes. Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
With schizophrenia, dopamine and glutamate were the most studied
neurotransmitters. The two transmitters have the following three
observations: 1) “stimulant drugs like amphetamine may produce
some symptoms similar to schizophrenia in normal individuals and
exacerbate underlying positive symptoms in individuals who have
schizophrenia” (Advokat, Comaty & Julien, 2018, P. 382). 2) “drugs
such as phencyclidine (PCP) and ketamine can also exacerbate
positive symptoms in individuals who have schizophrenia” ”(Advokat,
Comaty & Julien, 2018, P. 382). And lastly, (3) “stimulants release
dopamine and phencyclidine and ketamine antagonize NMDA
(glutamate) receptors” (Advokat, Comaty & Julien, 2018, P. 382).
Therefore, based on the observations from the text, there has been
continuous interest in the understanding of the two neurotransmitters
or even the possibility of combinations of the neurotransmitters
involving the pathophysiology of schizophrenia. Furthermore, there
has been a number of theories about the neurochemical blockages that
would discuss the development of schizophrenia, there is no indication
of the neurochemical models explaining the phenotypic display of
behaviors related to schizophrenia.
As previously discussed, dopamine and glutamate were the most
studied transmitters in regard to schizophrenia. But research shows
that serotonin and genetics have contributed to schizophrenia. In this
case lets discuss serotonin, in addition to the symptomology of
schizophrenia. Psychedelic drugs (i.e. LSD) can cause hallucinations.
LSD and other drugs were first proposed to be involved in the analytic
disorder seen in schizophrenia. According to the text, it was
hypothesized that “5-HT2 receptor antagonism might be responsible
for some of the beneficial actions of antipsychotics” (Advokat,
Comaty & Julien, 2018, P.384). Even though it has been determined
that serotonin does not play a major role in the analysis of
schizophrenia , antagonism of serotonin at 5-HT receptors may be₂
beneficial in the improvement of the neurological side effect profile of
the newer edition of the antipsychotic medications.
Schizophrenia is considered to be a disorder of the brain changing the
way a individual (s) thinks, behaves and feels. However, other than
the brain, schizophrenia can also show a change. The symptoms of
schizophrenia are pretty much self- explanatory those included:
hearing or seeing something that isn’t there or a constant feeling of
being watched in other words hallucinations that is a change that you
would see in an individuals brain, another change would be weight
gain and a possibility of developing type 2 diabetes, individuals
dealing with schizophrenia have challenges with exercise and diet.
Even though, there is no specific cause (s) of schizophrenia this does
not get in the way of the fact that schizophrenia is a serious issue in
America.
Over time the treatment of schizophrenia has evolved. Moreover, in
the context of the development of antipsychotic drug development.
Although there has been important progress resulting in the
availability and the usage on a number of medications, the three basic
classes of medications: conventional [typical], atypical and dopamine
partial agonist antipsychotics, all of despite working by a various of
mechanism of actions, acts mainly on the dopamine systems. The
atypical and dopamine partial agonist antipsychotics offer advantages
over the ‘firstgeneration’ in the treatment for schizophrenia. However,
the pharmacological concepts that confer the different types of
therapeutic effects of the most recent generation of antipsychotic
drugs have remained ambiguous, and certain effects can impact
patient health and the quality of life. The efficacy of antipsychotic
drugs is limited giving the clinical use of ancillary pharmacy to
enhance the effects of treatment. Additionally, the search for
nondopaminergic antipsychotic drugs has been unsuccessful to date,
although many development strategies are continuing to be determine,
guided by different pathophysiologic theories.
In conclusion, Schizophrenia is a “chronic brain disorder that affects
less than 1% of the U.S. population” (American Psychiatric
Association, 2017, para. 1). Symptoms of this disorder include
hallucinations/delusions, challenges with thinking and concentrating,
also a lack of motivation including impaired cognition and
disorganization (i.e, Abnormal movements). There are often
misconceptions in regard to schizophrenia, most people dealing with
this disorder are not violent or dangerous. Most people dealing with
Schizophrenia may live with family, in group homes or living on their
own. There are no cause(s) when it comes to schizophrenia, some
research says its genetics and other research it says that schizophrenia
is a combination of multiple disorders. Any drug that are proven to be
effective in the treatment of schizophrenia has to block the dopamine
receptors, mainly the D receptor. Schizophrenia can appear in late₂
adolescent or early adulthood. Keep in mind, despite the symptoms
some people dealing with schizophrenia are often able to lead
productable lives without getting in trouble but with the proper
treatment.
